EU Parallel Trade ‘Alleviates Shortages’ Says New EAEPC President
Parallel traders play a major role in injecting competition into the EU pharmaceutical market place and alleviating drug shortages, says Kohlpharma’s Jörg Geller, who has just taken over at the helm of the parallel distributors’ representative body in Europe.
You may also be interested in...
There are now 31 medicines on the UK’s list of products that cannot be parallel exported to other European Economic Area countries as part of government efforts to tackle drug shortages. The parallel trade industry has attacked the initiative for lack of transparency.
As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats.
Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.